A phase II study of PXD101 in advanced multiple myeloma.

被引：9

作者：

Sullivan, Daniel

Singhal, Seema

Schuster, Michael

Berenson, James

Gimsing, Peter

Wisloff, Finn

Waage, Anders

Alsina, Melissa

Gerwien, Robert

Clarke, Anne

Moller, Karen

Ooi, Chean Eng

机构：

[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[2] Northwestern Univ, Chicago, IL 60611 USA

[3] Cornell Univ, Weill Med Coll, New York, NY USA

[4] Myeloma & Bone Canc Res, W Hollywood, CA USA

[5] Rigshosp, DK-2100 Copenhagen, Denmark

[6] Ulleval Univ, Oslo, Norway

[7] St Olavs Hosp, Trondheim, Norway

[8] CuraGen Corp, Branford, CT USA

[9] TopoTarget, Copenhagen, Denmark

来源：

BLOOD | 2006年 / 108卷 / 11期

关键词：

D O I：

10.1182/blood.V108.11.3583.3583

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3583

引用

页码：1023A / 1023A

页数：1

共 50 条

[1] A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors
Kelly, W. K.
Yap, T.
Lee, J.
Lassen, U.
Crowley, E.
Clarke, A.
Hawthorne, T.
Buhl-Jensen, P.
de Bono, J.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[2] A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors
Molife, Rhoda
Lee, James
Petrylak, Daniel
Blumenschein, George, Jr.
Lassen, Ulrik
Clark, Jayme
Yap, Timothy
Rowen, Elin
Ang, Jooern
Crowley, Elizabeth
Clarke, Anne
Hawthorne, Thomas
Buhl-Jensen, Peter
De Bono, Johann
Kelly, Wm Kevin
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3476S - 3476S
[3] A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocelluar carcinoma
Yeo, W.
Lim, R.
Ma, B. B.
Hui, P.
Chan, L.
Mo, F. K.
Yu, S. C.
Ho, S. S.
Koh, J.
Chan, A. T.
Goh, B.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[4] A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors
Northfelt, D. W.
Marschke, R. F., Jr.
Bonnem, E.
Ooi, C. E.
Gerwien, R.
Hawthorne, T.
Clarke, A.
Buhl-Jensen, P.
Von Hoff, D.
Grem, J.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[5] A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors
Hansen, M
Gimsing, P
Rasmussen, A
Jensen, PB
Knudsen, LM
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 225S - 225S
[6] A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors and lymphoma
O'Bryant, Cindy L.
Leong, Stephen
Camidge, D. Ross
Gore, Lia
Diab, Sami
Gustafson, Dan L.
Call, Justin
Spratlin, Jennifer
Zwiebel, James A.
Eckhardt, S. Gail
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3384S - 3384S
[7] A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma
Nallapareddy, Sujatha
Leong, Stephen
Camidge, Ross
Gore, Lia
Diab, Sami
Messersmith, Wells
Lewis, Karl
Weekes, Colin
Gustafson, Daniel
Jimeno, Antonio
Zwiebel, James
-Delgado, Igor Espinoza
Eckhardt, Gail
O'Bryant, Cindy
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[8] Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
Ramalingam, Suresh S.
Belani, Chandra. P.
Ruel, Christopher
Frankel, Paul
Gitlitz, Barbara
Koczywas, Marianna
Espinoza-Delgado, Igor
Gandara, David
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (01) : 97 - 101
[9] Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms
Odenike, O.
Green, M.
Larson, R. A.
Rich, E. S.
Ott, J.
Ratain, M. J.
Stock, W.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[10] Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
Cashen, Amanda
Juckett, Mark
Jumonville, Alcee
Litzow, Mark
Flynn, P. J.
Eckardt, John
LaPlant, Betsy
Laumann, Kristina
Erlichman, Charles
DiPersio, John
ANNALS OF HEMATOLOGY, 2012, 91 (01) : 33 - 38

← 1 2 3 4 5 →